Patent SG-11201901594R-A (SG)
Title: Cell suspension for use in the treatment of lower extremity peripheral artery disease
Inventor: DUPERE JONATHAN ROBERT BARCLAY
IPC: C12N5/0789
Filed: 2017-08-28
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 March 2018 (01.03.2018) W I PO I PCT ill~~~~~~~~ 011101110VIIIOH olo oui olow mina° oimIE (10) International Publication Number WO 2018/037134 Al (51) International Patent Classification: C12N 5/078 (2010.01) C12N 5/0789 (2010.01) (21) International Application Number: PCT/EP2017/071580 (22) International Filing Date: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: (26) Publication Language: (30) Priority Data: 16382405.5 28 August 2017 (28.08.2017) English English 26 August 2016 (26.08.2016) EP Published: — with international search report (Art. 21(3)) (71) Applicants: REXGENERO BIOSCIENCES, S.L. [ES/ES]; Calle Max Planck 3, (Ed. Iris II, Isla de la Cartuja), 41092 Sevilla (ES). SERVICIO ANDALUZ DE SALUD [ES/ES]; Avda. de la Constitucion, 18, 41071 Sevilla (ES). FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD [ES/ES]; Avda. Americo Vespucio, 15, Edificio S2., Parque Cientifico y Tecnologico Cartuja, 41092 Sevil- la (ES). = (72) Inventors: DUPERE, Jonathan Robert Barclay; Rex- genero Biosciences S.L., Calle Max Planck 3., (Ed. Iris II, Isla de la Cartuja), 41092 Sevilla (ES). DE JONG, LIes- beth; Rexgenero Biosciences S.L., Calle Max Planck 3., (Ed. Iris II, Isla de la Cartuja), 41092 Sevilla (ES). WA- GENA, Edwin J; Rexgenero Biosciences S.L., Calle Max Planck 3., (Ed. Iris II, Isla de la Cartuj a), 41092 Sevilla (ES). (74) Agent: HOFFMANN EITLE, S.L.U.; Paseo de la Castel- lana 140, Planta 3', Edificio Lima, 28046 Madrid (ES). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: CELL SUSPENSION FOR USE IN THE TREATMENT OF LOWER EXTREMITY PERIPHERAL ARTERY DISEASE (57) : The present invention refers to a cell suspension of autologous or allogeneic, preferably autologous, adult bone mar- row-derived white blood cells, preferably derived from the crest of the ilium (or iliac crest), enriched for mononuclear cells, meaning more than 25% of the white blood cells (WBCs) present in the cell suspension are mononuclear cells, and comprising: A.Mononuclear cells (MNC) selected from the list comprising or consisting of: i. A population of Lymphocytes; ii. A population of Monocytes; and iii. A population of Hematopoietic stem cells expressing CD34; and wherein the cell suspension further comprises: B.Granulocytes; for use in the treatment or amelioration of lower extremity peripheral artery disease. 1-1 N O co O C